TRIGGER
The Twice-Monthly Electronic Newsletter on the Biology of Tissue Factor, Factor VII and TFPI
Vol. 19, No. 15 July 31, 2013
__________________________________________________________
TRIGGER is also available by RSS Feed:
and BLOG:
http://trigger-tf7.blogspot.com/
__________________________________________________________
UPCOMING MEETINGS & EVENTS
The Twice-Monthly Electronic Newsletter on the Biology of Tissue Factor, Factor VII and TFPI
Vol. 19, No. 15 July 31, 2013
(The next issue will be on August 15, 2013)
TRIGGER is also available by RSS Feed:
and BLOG:
http://trigger-tf7.blogspot.com/
__________________________________________________________
PAPERS IN PRESS
SUBMITTED BY: Jim Morrissey <jhmorris@illinois.edu>
__________________________________________________________
AUTHORS: Tavoosi N, Smith SA, Davis-Harrison RL, and
Morrissey JH
TITLE: Factor VII
and Protein C are Phosphatidic Acid-Binding Proteins
JOURNAL: Biochemistry
ABSTRACT: Seven proteins in the human blood clotting
cascade bind, via their GLA (gamma-carboxyglutamate-rich) domains, to membranes
containing exposed phosphatidylserine (PS), although with membrane binding
affinities that vary by three orders of magnitude. Here we employed Nanodiscs
of defined phospholipid composition to quantify the phospholipid binding
specificities of these seven clotting proteins. All bound preferentially to
nanobilayers in which PS headgroups contained L-serine versus D-serine.
Surprisingly, however, nanobilayers containing phosphatidic acid (PA) bound
substantially more of two of these proteins-factor VIIa and activated protein
C-than did equivalent bilayers containing PS. Consistent with this finding,
liposomes containing PA supported higher proteolytic activity by factor VIIa
and activated protein C toward their natural substrates (factors X and Va,
respectively) than did PS-containing liposomes. Moreover, treating activated
human platelets with phospholipase D enhanced the rates of factor X activation
by factor VIIa in the presence of soluble tissue factor. We hypothesize that
factor VII and protein C bind preferentially to the monoester phosphate of PA
because of its accessibility and higher negative charge compared to the diester
phosphates of most other phospholipids. We further found that
phosphatidylinositol 4-phosphate, which contains a monoester phosphate attached
to its myo-inositol headgroup, also supported enhanced enzymatic activity of
factor VIIa and activated protein C. We conclude that factor VII and protein C
bind preferentially to monoester phosphates, which may have implications for
the function of these proteases in vivo.
UPCOMING MEETINGS & EVENTS
2013 ASH Annual Meeting will be held in New Orleans, LA,
December 7-10, 2013. Abstract deadline is August 8, 2013. More info:
*** ***
*** ***
2014 Gordon Research Conference on Plasminogen Activation
& Extracellular Proteolysis will be held February 9-14, 2014 in Ventura,
CA. More info:
*** ***
*** ***
Thrombosis and Hemostasis Summit of North America (THSNA)
meeting will be held in Chicago, IL, April 10-12, 2014. Early registration
deadline December 1, 2013; abstract submission starts September 2013.
More info:
*** ***
*** ***
2014 ATVB Meeting will be held May 1-3, 2014 in Toronto,
Canada. More info:
*** ***
*** ***
7th Symposium on Hemostasis will be held at the Carolina
Inn, Chapel Hill, NC, May 15-17, 2014. Focus will include tissue factor,
coagulation proteases and their role in hemostasis and thrombosis, as well as
interplay between coagulation and inflammation More info:
*** ***
*** ***
2014 Hemostasis Gordon Research Conference will be held
July 27 to August 1, 2014, in Waterville, NH. It will be preceded by a two-day
Gordon Research Seminar July 26-27 for postdocs and graduate students. More
info:
*** ***
*** ***
General info on upcoming meetings of interest:
ISTH also has a list of upcoming meetings of interest:
__________________________________________________________
RECENT PUBLICATIONS ON TISSUE FACTOR, FACTOR VII, AND TFPI
RECENT PUBLICATIONS ON TISSUE FACTOR, FACTOR VII, AND TFPI
Papers are culled from NLM MedLine (PubMed). Titles in square brackets indicate that the paper was not published in English. References that lack volume or page numbers are typically electronic pre-publications (E-pubs) ahead of the print publication; if so, the final citation with volume and page numbers may or may not appear in a future issue of Trigger.
THE FOLLOWING LINK WILL TAKE YOU TO THE ENTIRE LIST OF THIS ISSUE'S PUBLICATIONS IN A PUBMED "COLLECTION":
(2013) Bleeding
with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical
experience. Prescrire Int 22:155-159.
Awad E, Khan S, Sokolikova B, Brunner P, Olcaydu D, Wojta
J, . . .
Uhrin P (2013) Cold induces ROS-production and activation
of the NF-kappa B response in endothelial cells and inflammation in vivo. J
Thromb Haemost.
Bakhtiari K, Kamphuisen PW, Mancuso ME, Hamulyak K,
Schutgens RE, Santagostino E, Meijers JC (2013) Clot lysis phenotype and
response to recombinant factor VIIa in plasma of haemophilia A inhibitor
patients. Br J Haematol.
Barone I, Meccariello G, Cazzato L, Capalbo SF, Matteo M,
Greco P
(2013) Management of platelet storage pool disease during
pregnancy with recombinant factor VIIa. Eur J Obstet Gynecol Reprod Biol.
Bharthuar A, Khorana AA, Hutson A, Wang JG, Key NS,
Mackman N, Iyer RV (2013) Circulating microparticle tissue factor,
thromboembolism and survival in pancreaticobiliary cancers. Thromb Res.
Brand HS, Veerman EC (2013) Saliva and wound healing. Chin
J Dent Res 16:7-12.
Chen VM (2013) Tissue factor de-encryption, thrombus
formation, and thiol-disulfide exchange. Semin Thromb Hemost 39:40-47.
Chen VM, Hogg PJ (2013) Encryption and decryption of
tissue factor. J Thromb Haemost 11 Suppl 1:277-284.
Cho AH, Khosla R (2013) A Case of Massive Airway Clotting
After Use of Activated Factor VII for Massive Hemoptysis: Management With
Flexible Bronchoscopy and Cryoadhesion. J Bronchology Interv Pulmonol
20:276-277.
Cole M, Bromberg M (2013) Tissue factor as a novel target
for treatment of breast cancer. Oncologist 18:14-18.
Denas G, Pengo V (2013) Investigational anticoagulants
for hematological conditions: a new generation of therapies. Expert Opin
Investig Drugs.
Emekli-Alturfan E, Yarat A, Caliskan-Ak E, Pisiriciler R,
Kuru B, Noyan U (2013) Determination of storage time of saliva samples obtained
from patients with and without chronic periodontitis for the comparison of some
biochemical and cytological parameters. J Clin Lab Anal 27:261-266.
Gushchina LV, Yasmeen R, Ziouzenkova O (2013) Moderate
vitamin A supplementation in obese mice regulates tissue factor and cytokine
production in a sex-specific manner. Arch Biochem Biophys.
Huang ZJ, Zhao Y, Luo WY, You J, Li SW, Yi WC, . . . Luo
Q (2013) Targeting the Vasculature of Colorectal Carcinoma with a Fused Protein
of (RGD)3-tTF. ScientificWorldJournal 2013:637086.
Jiang MH, Wang ZY, Yu ZQ, Su J, Cao LJ, Zhang W (2013)
[Identification and functional analysis of a novel missense mutation Ser250Phe
underlying congenital coagulation factor deficiency].
Zhonghua Yi Xue Yi Chuan Xue Za Zhi 30:152-156.
Kambas K, Chrysanthopoulou A, Vassilopoulos D,
Apostolidou E, Skendros P, Girod A, . . . Mitroulis I (2013) Tissue factor
expression in neutrophil extracellular traps and neutrophil derived
microparticles in antineutrophil cytoplasmic antibody associated vasculitis may
promote thromboinflammation and the thrombophilic state associated with the
disease. Ann Rheum Dis.
Kocaturk B, Versteeg HH (2013) Tissue factor-integrin
interactions in cancer and thrombosis: every Jack has his Jill. J Thromb
Haemost 11 Suppl 1:285-293.
Korhonen TK, Haiko J, Laakkonen L, Jarvinen HM,
Westerlund-Wikstrom B
(2013) Fibrinolytic and coagulative activities of. Front
Cell Infect Microbiol 3:35.
Lima LG, Monteiro RQ (2013) Activation of blood
coagulation in
cancer: implications for tumor progression. Biosci Rep.
Lippi G, Favaloro EJ, Cervellin G (2013) Massive
posttraumatic
bleeding: epidemiology, causes, clinical features, and
therapeutic management. Semin Thromb Hemost 39:83-93.
Lupu C, Herlea O, Tang H, Lijnen RH, Lupu F (2013)
Plasmin-dependent proteolysis of tissue factor pathway inhibitor in a mouse
model of endotoxemia. J Thromb Haemost 11:142-148.
Mathias M, Tunstall O, Khair K, Liesner R (2013)
Management of surgical procedures in children with severe FV deficiency:
experience of 13 surgeries. Haemophilia 19:256-258.
Mita-Mendoza NK, van de Hoef DL, Lopera-Mesa TM, Doumbia
S, Konate D, Doumbouya M, . . . Fairhurst RM (2013) A potential role for plasma
uric acid in the endothelial pathology of Plasmodium falciparum malaria. PLoS
One 8:e54481.
Monroe DM, Hoffman M, Roberts HR, Hedner U (2013) Progressive
improvement in wound healing with increased therapy in haemophilia B mice.
Haemophilia.
Nakabayashi T, Gotoh Y, Kamada N, Fujioka M, Ishihara T,
Hirabayashi A, Sato H (2013) Characterization of in vitro biotransformation of
the new oral anticoagulants, the factor VIIa inhibitors AS1927819-00 and
AS1932804-00. Pharmazie 68:406-413.
Nakabayashi T, Gotoh Y, Kamada N, Fujioka M, Ishihara T,
Hirabayashi A, Sato H (2013) Pharmacokinetics of the amidine prodrug of a novel
oral anticoagulant factor VIIa inhibitor (AS1924269-00) in rats.
Pharmazie 68:349-354.
Neufeld EJ, Saxena K, Kessler CM, Cooper DL (2013)
Dosing, efficacy, and safety of recombinant factor VIIa (rFVIIa) in pediatric
versus adult patients: the experience of the Hemostasis and Thrombosis Research
Society (HTRS) Registry (2004-2008). Pediatr Blood Cancer 60:1178-1183.
Ng C, Silliman CC, Pearl G, Smith W, Manco-Johnson M,
Wang M (2013) Treatment of refractory hemorrhage with Factor XIII in a patient
with hemophilia A with inhibitor. Pediatr Blood Cancer 60:E23-25.
Ngo Sack F, Galinat H, Egreteau PY, Mollard LM, Fortin H,
Berthou C, . . . Pan-Petesch B (2013) Efficacy of rituximab in acquired factor
XIII inhibitor after arterial rFVIIa-induced thrombosis. Haemophilia 19:e93-94.
Nie XM, Su LX, Xu RX, Guo YL, Zhou YJ, Li JJ (2013)
Kruppel-like factor 2 might mediate the rapamycin-induced arterial thrombosis
in
vivo: implications for stent thrombosis in patients. Chin
Med J
(Engl) 126:2636-2640.
Okamoto Y, Ishii S, Croce K, Katsumata H, Fukushima M,
Kihara S, . .
. Minami S (2013) Adiponectin inhibits macrophage tissue
factor, a key trigger of thrombosis in disrupted atherosclerotic plaques.
Atherosclerosis 226:373-377.
Oku K, Amengual O, Zigon P, Horita T, Yasuda S, Atsumi T
(2013) Essential role of the p38 mitogen-activated protein kinase pathway in
tissue factor gene expression mediated by the phosphatidylserine-dependent
antiprothrombin antibody. Rheumatology (Oxford).
Peyvandi F, Garagiola I, Seregni S (2013) Future of
coagulation factor replacement therapy. J Thromb Haemost 11 Suppl 1:84-98.
Peyvandi F, Menegatti M, Palla R (2013) Rare Bleeding
Disorders:
Worldwide Efforts for Classification, Diagnosis, and
Management.
Semin Thromb Hemost.
Rao B, Gao Y, Zhou Q, Xiao P, Xia S, Ma J, . . . Wang J
(2013) A recombinant adenovirus vector encoding the light chain of human
coagulation factor VII and IgG1 Fc fragment to targeting tissue factor for
colorectal cancer immunotherapy in the mouse model. J Cancer Res Clin Oncol
139:1015-1023.
Sakowicz A, Fendler W, Lelonek M, Sakowicz B, Pietrucha T
(2013) Genetic polymorphisms and the risk of myocardial infarction in patients
under 45 years of age. Biochem Genet 51:230-242.
Schulz C, Engelmann B, Massberg S (2013) Crossroads of
coagulation and innate immunity: the case of deep vein thrombosis. J Thromb
Haemost 11 Suppl 1:233-241.
Sergeeva AM, Mazurok VA, Zakirov II, Kichigin VA (2013)
[Recombinant activated factor VII use for the bleeding implications prevention
during central venous catheterization in pediatric patients with acute leucosis
and thrombocytopenia]. Anesteziol Reanimatol:18-21.
Shirahata A, Fukutake K, Mimaya J, Takamatsu J, Shima M,
Hanabusa H, . . . Saito H (2013) Results of clot waveform analysis and thrombin
generation test for a plasma-derived factor VIIa and X mixture
(MC710) in haemophilia patients with inhibitors--phase I
trial: 2nd report. Haemophilia 19:330-337.
Shrestha C, Ito T, Kawahara KI, Shrestha B, Yamakuchi M,
Hashiguchi T, Maruyama I (2013) Saturated fatty acid palmitate induces
extracellular release of histone H3: A possible mechanistic basis for high-fat
diet-induced inflammation and thrombosis. Biochem Biophys Res Commun.
Sridharan V, Tripathi P, Sharma S, Corry PM, Moros EG,
Singh A, . . .
Boerma M (2013) Effects of late administration of
pentoxifylline and tocotrienols in an image-guided rat model of localized heart
irradiation. PLoS One 8:e68762.
Stavik B, Tinholt M, Sletten M, Skretting G, Sandset PM,
Iversen N
(2013) TFPIalpha and TFPIbeta are expressed at the
surface of breast cancer cells and inhibit TF-FVIIa activity. J Hematol Oncol
6:5.
Sternberg Z, Ghanim H, Gillotti KM, Tario JD, Jr.,
Munschauer F, Curl R, . . . Dandona P (2013) Flow cytometry and gene expression
profiling of immune cells of the carotid plaque and peripheral blood.
Atherosclerosis 229:338-347.
Tavoosi N, Smith SA, Davis-Harrison RL, Morrissey JH
(2013) Factor VII and Protein C are Phosphatidic Acid-Binding Proteins.
Biochemistry.
Tomkiewicz-Pajak L, Hoffman P, Trojnarska O, Lipczynska
M, Podolec P, Undas A (2013) Abnormalities in blood coagulation, fibrinolysis,
and platelet activation in adult patients after the Fontan procedure. J Thorac
Cardiovasc Surg.
Vadivel K, Agah S, Messer AS, Cascio D, Bajaj MS,
Krishnaswamy S, . .
. Bajaj SP (2013) Structural and functional studies of
gamma-carboxyglutamic acid domains of factor VIIa and activated Protein C: role
of magnesium at physiological calcium. J Mol Biol 425:1961-1981.
Xu Y, Zhang X, Zhao Y, Zhao L, Qiu H, Wu D (2013)
Successful treatment of a patient with acquired haemophilia A with a
combination of a low-dose rituximab and recombinant human FVIIa. Haemophilia
19:e95-96.
Yang L, Rezaie AR (2013) Residues of the 39-loop restrict
the plasma inhibitor specificity of factor IXa. J Biol Chem 288:12692-12698.
Zhang TL, Liu B, Zhang P, Xing XH, Meng YS, Lan QL (2013)
[A family with hereditary coagulation factor deficiency]. Zhonghua Yi Xue Yi
Chuan Xue Za Zhi 30:126.
Zhao Y, Fu Y, Hu J, Liu Y, Yin X (2013) The effect of
tissue factor pathway inhibitor on the expression of monocyte chemotactic
protein-3 and IkappaB-alpha stimulated by tumour necrosis factor-alpha in
cultured vascular smooth muscle cells. Arch Cardiovasc Dis 106:4-11.
Zhu H, Liang B, Li R, Li J, Lin L, Ma S, Wang J (2013)
Activation of coagulation, anti-coagulation, fibrinolysis and the complement
system in patients with urticaria. Asian Pac J Allergy Immunol 31:43-50.
http://www.ncbi.nlm.nih.gov/pubmed/23517393
__________________________________________________________
TRIGGER is edited by Jim Morrissey and Pierre Neuenschwander, with editorial assistance by Genie Morrissey. It includes Abstracts of Papers in Press, Meeting Announcements, Positions Sought/Available,or any other pertinent item that subscribers may want to share with their colleagues. To submit an item for publication in Trigger, e-mail us. To request or cancel a subscription,or for more information about TRIGGER or the biology of tissue factor and factor VII, visit our web site. You can also contact us by mail: J.H. Morrissey, University of Illinois College of Medicine, 417 Med Sci Bldg MC-714, 506 S. Mathews Ave., Urbana, IL 61801, USA.
DISCLAIMER: TRIGGER is provided "as is" for information purposes only and without warranty of any kind, express or implied. Users shall assume the entire risk as to the accuracy and usefulness of information in TRIGGER. Opinions expressed here are not necessarily those of the editors or their employers. You may share TRIGGER with your scientific colleagues but you are not permitted to use it or its contents for commercial purposes.
__________________________________________________________
No comments:
Post a Comment